Pierre Fabre Laboratories has committed to improving its global customer relationship management (CRM) measures after agreeing a new deal with Cegedim Dendrite.
The healthcare company has confirmed a five-year framework agreement with the CRM specialist in order to strengthen its medical sales activities in a number of global territories.
These will initially be centred on the pharmaceuticals market, with Pierre Fabre also planning to leverage Cegedim Dendrite solutions for its over-the-counter and dermo-cosmetics activities further down the line.
Pierre Fabre stated that this decision comes as part of the firm's ongoing expansion, adding that it hopes to take advantage of Cegedim Dendrite's worldwide presence.
Laurent Labrune, chief executive officer of Cegedim Dendrite, said: "This type of agreement validates our unique positioning to offer our clients solutions that are in tune with their various specialties."
Last month, the company confirmed a deal with fellow pharmaceuticals firm Abbott over the licensing of h224G11, a monoclonal antibody with potential cancer care applications.